Skip to main content
. 2022 Aug 22;13:872196. doi: 10.3389/fphar.2022.872196

TABLE 3.

Results of the base-case analysis and subgroup analysis.

Country Regimen LY QALY Cost, US$ ICER ($/LY) ICUR ($/QALY)
US Placebo plus chemotherapy 1.957 1.419 62,422 - -
Atezolizumab plus chemotherapy 2.290 1.651 233,492 513,724 737,371
China Placebo plus chemotherapy 1.957 1.365 9,912 - -
Atezolizumab plus chemotherapy 2.290 1.580 96,946 261,363 404,809

LY, life-year; QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio; ICUR, incremental cost–utility ratio.